

DRUG DISCOVERY TODAY**Editorial**

Editor: Steve Carney
Assistant Editor: Kirsty Strawbridge
Content Development Manager: Joanna Aldred
Journal Manager: Basil Nyaku
Publisher: Jaap van Harten
Editorial Enquiries:
Drug Discovery Today
 Elsevier
 32 Jamestown Road, London, NW1 7BY, UK
 Tel: +44 (0)20 7424 4200
 Fax: +44 (0)1865 853067
 Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD

Jurgen Bajorath *University of Bonn, Germany*
Walter Blackstock *Experimental Therapeutics Centre, Singapore*
David Brayden *University College Dublin, Ireland*
Paul Caron *Vertex Pharmaceuticals, USA*
David Cavalla *Arachnova, UK*
David Clark *Argenta Discovery, UK*
Dalia Cohen *Rosetta Genomics, USA*
Donald Daley *Argenta Discovery, UK*
Sean Ekins *ACT LLC and Collaborations in Chemistry, USA*
Hans-Peter Fischer *GeneData, Switzerland*
Peter Ghazal *University of Edinburgh, UK*
Christopher M. Hill *Organon, UK*
Nick Hird *Takeda Chemical Industries, Japan*
Enoch Huang *Pfizer, USA*
Thomas Joos *University of Tuebingen, Germany*
Vincent H.L. Lee *Chinese University of Hong Kong, Hong Kong*
David Lewin *Yale University, USA*
Christopher A. Lipinski *Melior Discovery, USA*
Lorenz Mayr *Novartis, Switzerland*
Nick Meanwell *Bristol-Myers Squibb, USA*
BK Muralidhara *Pfizer Global Biologics, St. Louis, USA*
Mark Murcko *Vertex Pharmaceuticals, USA*
Fajun Nan *Shanghai Institute of Materia Medica, China*
Pradeep Nathan *Experimental Medicine, GSK and University of Cambridge*
Gitte Neubauer *Cellzome, Germany*
Eric Neumann *Teranode, USA*
Tim Peakman *UK Biobank, UK*
Norton Peet *Aurigene, USA*
Manuel Peitsch *Novartis, Switzerland*
Kurt Rasmussen *Eli Lilly and Co. Ltd. USA*
Janice Reichert *Tufts Center for the Study of Drug Development, USA*
John Reidhaar-Olson *Hoffmann-La Roche, USA*
Mike Romanos *GlaxoSmithKline, UK*
Raymond C. Rowe *Intelligensys, UK*
Andreas Russ *University of Oxford, UK*
Esther Schmid *Pfizer, UK*
Jonathan Sheldon *Inforsense, UK*
Michael Snyder *Yale University, USA*
Susie Stephens *Eli Lilly and Co. Ltd., USA*
Robert Strausberg *The J. Craig Venter Institute, USA*
Donny Strosberg *Scripps Florida, USA*
Yuichi Sugiyama *University of Tokyo, Japan*
David Szymkowski *Xencor, USA*
Nick Terrett *Ensemble Discovery, USA*
Vladimir Torchilin *Northeastern University, Boston, USA*
Mark Whittaker *Evotec OAI, UK*
Hans Winkler *Johnson and Johnson, Belgium*
Limsoon Wong *Laboratories for Information Technology (LIT), Singapore*
X.F. Steven Zheng *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY TODAY

EDITORIAL**815 Going to the dark side: success factors for companies leveraging senior academic talent**

Joanne W. Yun

PERSPECTIVE**FEATURE****818 Biotech acquisitions by big pharma: why and what is next**

Nafees N. Malik

MONITOR**905 Orally bioavailable proteasome inhibitors: preclinical development of PR-047**

Kevin Peese

907 DIARY**FORTHCOMING ARTICLES:****From osteoarthritis treatments to future regenerative therapies for cartilage**

by Johann Clouet, Claire Vinatier, Christophe Merceron, Marianne Pot-Vaucel, Yves Maugars, Pierre Weiss, Gaël Grimandi and Jérôme Guicheux

Understanding autoimmune disease: new targets for drug discovery

by Cristina Balagué, Steven L. Kunkel and Núria Godessart

Digital pathology in drug discovery and development: multi-site integration

by Steven J. Potts

From pumps to prevention: recent advances in the treatment of type 1 diabetes

by Jennifer Sherr, Eda Cengiz and William V. Tamborlane